Moleculin rises on positive trial data for a type of cancer treatment

Moleculin Biotech

06/11/2023 18:12

** Shares of drug developer Moleculin Biotech  MBRX.O  rise
~16% to 59 cents
    ** Company says its experimental drug Annamycin showed
positive preliminary findings in an early- to mid-stage trial
for the treatment of soft tissue sarcoma lung metastases
    ** Soft tissue sarcoma lung metastases are cancers that
start in soft tissues (muscle, tendons, fat, lymph and blood
vessels and nerves) and spread to the lung
    ** Including session moves, stock down ~45.5% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))